IPHA Backs Call For More Patient Involvement In Evaluating New Treatments
Patients should have a greater say in the evaluation of new treatments, according to the Irish Pharmaceutical Healthcare Association (IPHA), the representative organisation for the originator pharmaceutical industry.
IPHA’s call came following the publication of a report by IQVIA, ‘Assessing Person-Centered Therapeutic Innovations’, which urged the inclusion of patient experience and patient preferences in Health Technology Assessment (HTA) evaluation, and pricing and reimbursement decisions.
Person-centered therapeutic innovations can have a significant impact on patients’ quality of life, improve adherence and, as a consequence, deliver better outcomes. Yet, the report shows that many HTA bodies and payers do not consider person-centered therapeutic innovations meaningfully in their evaluation of new treatments.
Oliver O’Connor, IPHA Chief Executive, said: “The inclusion of the improvement of patient experience and patient preferences in HTA evaluation and pricing and reimbursement decisions is necessary. Person-centered therapeutic innovations can have a significant impact on patients’ quality of life, improve adherence and, as a consequence, improve outcomes.”
The IQVIA report, commissioned by EFPIA, which represents Europe’s originator pharmaceutical industry, outlined the significant difference between how payers and end-users – patients and clinicians – perceive the value of person-centered therapeutic innovations. The report found that many payers and HTA bodies often overlook the added value of these innovations. Many HTA bodies do not consider patient experience benefits in their own right, favouring a more singular focus on clinical outcomes.
David Haerry of the European Aids Treatment Group welcomed the report. “HTA processes stand today where regulators found themselves 20 years ago – isolated from natural stakeholders and partners who have to cope with the consequences of their decision making. This report should be a wake-up call,” he said.
The white paper can be accessed Opens in new windowhere.
